Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27312730 | 0.88 | CA12 (0.40) | STAT3GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2130053 | 0.85 | STAT3 (0.44) | STAT3GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL3526985 | 0.83 | CA12 (0.43) | STAT3GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL480297 | 0.83 | ALDH1A1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3564657 | 0.82 | GABRA1 (0.41) | STAT3GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL14859175 | 0.82 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL5963476 | 0.81 | GABRA1 (0.41) | STAT3GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4518140 | 0.81 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6953347 | 0.80 | PDK1 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3527402 | 0.80 | CA12 (0.43) | STAT3GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373632-B1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER IP GMBH (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8859601-B2 | Substituted benzyl and phenylsulfonyl triazolones, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2373632-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-20110245308-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010063402-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | WO | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003000692-A2 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2003-01-03 | — | — | WO | disclosed |
| CN-1048159-C | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 2000-01-12 | — | — | CN | disclosed |
| EP-0955294-A2 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5418250-A | Hypotensive | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-23 | — | — | US | disclosed |
| US-5312828-A | Substituted imidazoles having angiotensin II receptor blocking activity | SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA | 1994-05-17 | — | — | US | disclosed |
| CN-1079648-A | Preparation contains the method for the pharmaceutical composition of imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 1993-12-22 | — | — | CN | disclosed |
| CN-1079649-A | Preparation contains the method for the pharmaceutical composition of imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 1993-12-22 | — | — | CN | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | STAT3 3379/4885GABRA1 105/4885GABRG2 187/4885 |
| US-20110245308-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | CHUK, BRSK2, IKBKE | STAT3 1531/4885GABRA1 1285/4885GABRG2 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.